ARCTURUS THERAPEUTICS HOLDIN (ARCT)
US03969T1097 - Common Stock
We assign a fundamental rating of 4 out of 10 to ARCT. ARCT was compared to 588 industry peers in the Biotechnology industry. ARCT has a great financial health rating, but its profitability evaluates not so good. ARCT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ARCT had negative earnings in the past year.
ARCT had a negative operating cash flow in the past year.
In the past 5 years ARCT reported 4 times negative net income.
ARCT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -6.92%, ARCT belongs to the best of the industry, outperforming 91.13% of the companies in the same industry.
ARCT has a Return On Equity of -10.67%. This is amongst the best in the industry. ARCT outperforms 91.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.92% | ||
| ROE | -10.67% | ||
| ROIC | N/A |
ROA(3y)-18.91%
ROA(5y)-20.7%
ROE(3y)-32.17%
ROE(5y)-43.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ARCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARCT has more shares outstanding
ARCT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ARCT has an Altman-Z score of 2.29. This is not the best score and indicates that ARCT is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.29, ARCT is doing good in the industry, outperforming 71.67% of the companies in the same industry.
There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.29 |
ROIC/WACCN/A
WACC9.18%
2.3 Liquidity
ARCT has a Current Ratio of 4.72. This indicates that ARCT is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.72, ARCT perfoms like the industry average, outperforming 51.88% of the companies in the same industry.
A Quick Ratio of 4.72 indicates that ARCT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.72, ARCT is in line with its industry, outperforming 52.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.72 | ||
| Quick Ratio | 4.72 |
3. Growth
3.1 Past
ARCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -405.88%.
Looking at the last year, ARCT shows a very negative growth in Revenue. The Revenue has decreased by -19.05% in the last year.
The Revenue has been growing by 60.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-405.88%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-107.22%
Revenue 1Y (TTM)-19.05%
Revenue growth 3Y159.91%
Revenue growth 5Y60.22%
Revenue growth Q2Q-80.75%
3.2 Future
ARCT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 110.02% yearly.
The Revenue is expected to grow by 43.61% on average over the next years. This is a very strong growth
EPS Next Y-130.05%
EPS Next 2Y60.79%
EPS Next 3Y99.92%
EPS Next 5Y110.02%
Revenue Next Year-13.43%
Revenue Next 2Y23.44%
Revenue Next 3Y42.54%
Revenue Next 5Y43.61%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ARCT's earnings are expected to grow with 99.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.79%
EPS Next 3Y99.92%
5. Dividend
5.1 Amount
No dividends for ARCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARCTURUS THERAPEUTICS HOLDIN
NASDAQ:ARCT (4/30/2024, 12:42:18 PM)
25.71
-0.92 (-3.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap692.11M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.92% | ||
| ROE | -10.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.72 | ||
| Quick Ratio | 4.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-405.88%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-130.05%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.05%
Revenue growth 3Y159.91%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y